Neuroblastoma Treatment Market size was valued at USD 442 billion in 2021, growing at a CAGR of 3.6% from 2022-28. The global market provides a detailed overview and that can be segmented by diagnostics, by drugs, and by treatment. By diagnostics, the global neuroblastoma treatment market has been segmented into MIBG Scan, Imaging, Urine Analysis, and Biopsy. The Imaging segment is likely to be the largest and fastest-growing segment in terms of type in 2021 and is expected to maintain the trend in the forecasted years. MIBG scan segment is also growing at a faster rate. Based on drugs, the global neuroblastoma treatment market is segmented Crizotinib, Doxorubicin Hydrochloride, Cyclophosphamide, Vincristine Sulfate, and Others. Among these, the Crizotinib segment is expected to have the fastest-growing market during the forecast period 2022-2028. It is attributed to the efficiency of the drug and high demand in the market. Also, Hydrochloride drugs has high demand in the global market and is expected to grow at a significant CAGR in the upcoming forecasted years. Based on treatment, the global neuroblastoma treatment market is segmented into Surgery, Chemotherapy, High-Dose Chemotherapy with Stem Cell Support, Monoclonal Antibody Treatment, Radiotherapy, and Others. The Surgery segment accounts for the largest share in 2021. Chemotherapy segment is the second-largest share during the forecast period 2022-2028 according to precision business insights. Although, high risk and side effects associated with Chemotherapy is restraining the growth of this segment at a significant rate. Key stakeholders of the market report include suppliers, manufacturers, marketers, policy makers, and healthcare service providers engaged in global neuroblastoma treatment products.
In Oct 2022, Cyclacel Pharmaceuticals announced that it will present preliminary dose escalation data from its ongoing 065-101 Phase 1/2 clinical trial of oral fadraciclib.